Amedeo Smart

Free Medical Literature Service


 

Amedeo

Epilepsy

  Free Subscription

Articles published in
Lancet
    April 2021
  1. MARSON A, Burnside G, Appleton R, Smith D, et al
    The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Lancet. 2021;397:1375-1386.
    >> Share

  2. MARSON A, Burnside G, Appleton R, Smith D, et al
    The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
    Lancet. 2021;397:1363-1374.
    >> Share

    December 2020
  3. BERKOVIC SF
    Epileptic encephalopathies of infancy: welcome advances.
    Lancet. 2020;394:2203-2204.
    >> Share

  4. LAGAE L, Sullivan J, Knupp K, Laux L, et al
    Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2020;394:2243-2254.
    >> Share

    June 2020
  5. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    >> Share

    March 2020
  6. CHAMBERLAIN JM, Kapur J, Shinnar S, Elm J, et al
    Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
    Lancet. 2020 Mar 20. pii: S0140-6736(20)30611.
    >> Share

  7. APPLETON RE
    Second-line anticonvulsants for paediatric convulsive status epilepticus.
    Lancet. 2020 Mar 20. pii: S0140-6736(20)30674.
    >> Share

    February 2020
  8. SEN A, Jette N, Husain M, Sander JW, et al
    Epilepsy in older people.
    Lancet. 2020;395:735-748.
    >> Share

    December 2019
  9. FODJO JNS, Makoy YL, Colebunders R
    Epilepsy prevention.
    Lancet. 2019;394:2072.
    >> Share

    June 2019
  10. THE LANCET
    Epilepsy prevention: an urgent global unmet need.
    Lancet. 2019;393:2564.
    >> Share

    April 2019
  11. SILBERGLEIT R, Elm JJ
    Levetiracetam no better than phenytoin in children with convulsive status epilepticus.
    Lancet. 2019 Apr 17. pii: S0140-6736(19)30896.
    >> Share

  12. DALZIEL SR, Borland ML, Furyk J, Bonisch M, et al
    Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.
    Lancet. 2019 Apr 17. pii: S0140-6736(19)30722.
    >> Share

  13. LYTTLE MD, Rainford NEA, Gamble C, Messahel S, et al
    Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
    Lancet. 2019 Apr 17. pii: S0140-6736(19)30724.
    >> Share

    February 2019
  14. THE LANCET
    From wonder and fear: make epilepsy a global health priority.
    Lancet. 2019;393:612.
    >> Share

    January 2019
  15. THIJS RD, Surges R, O'Brien TJ, Sander JW, et al
    Epilepsy in adults.
    Lancet. 2019 Jan 24. pii: S0140-6736(18)32596.
    >> Share

    August 2018
  16. SEN A, Nashef L
    New regulations to cut valproate-exposed pregnancies.
    Lancet. 2018;392:458-460.
    >> Share

    July 2018
  17. THE LANCET
    Cannabinoids: just like any other medication?
    Lancet. 2018;392:188.
    >> Share

    March 2018
  18. VARADKAR S
    Cannabidiol for drop seizures in Lennox-Gastaut syndrome.
    Lancet. 2018;391:1006-1007.
    >> Share

  19. THIELE EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, et al
    Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet. 2018;391:1085-1096.
    >> Share

    October 2016
  20. BAYER R, Johns DM, Galea S
    A false aura of scientific controversy around salt?
    Lancet. 2016;388:2109.
    >> Share

  21. FRENCH JA, Lawson JA, Yapici Z, Ikeda H, et al
    Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet. 2016;388:2153-2163.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016